<SEC-DOCUMENT>0001213900-22-014569.txt : 20220323
<SEC-HEADER>0001213900-22-014569.hdr.sgml : 20220323
<ACCEPTANCE-DATETIME>20220323180454
ACCESSION NUMBER:		0001213900-22-014569
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220321
FILED AS OF DATE:		20220323
DATE AS OF CHANGE:		20220323

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			EMSTER KURT VON
		CENTRAL INDEX KEY:			0001252524

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39138
		FILM NUMBER:		22764115

	MAIL ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD
		STREET 2:		SUITE 350
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Jasper Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001788028
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				842984849
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2200 BRIDGE PKWY SUITE #102
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		6505491400

	MAIL ADDRESS:	
		STREET 1:		2200 BRIDGE PKWY SUITE #102
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Amplitude Healthcare Acquisition Corp
		DATE OF NAME CHANGE:	20190912
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2022-03-21</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001788028</issuerCik>
        <issuerName>Jasper Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>JSPR</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001252524</rptOwnerCik>
            <rptOwnerName>EMSTER KURT VON</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O JASPER THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>2200 BRIDGE PKWY, SUITE #102</rptOwnerStreet2>
            <rptOwnerCity>REDWOOD CITY</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94065</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>3.54</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2022-03-21</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>78045</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2032-03-21</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Voting Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>78045</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>78045</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">1/3rd of the shares subject to the option (the &quot;Option&quot;) shall vest on December 7, 2022, and 1/3rd of the shares subject to the Option shall vest on each anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.</footnote>
        <footnote id="F2">The Reporting Person is a member of the investment committee of Abingworth Bioventures VII, LP (&quot;ABV VII&quot;) which approves investment and voting decisions by majority vote. Abingworth LLP provides advisory services to ABV VII and exercises investment and dispositive power over the securities held by ABV VII. Under an agreement between the Reporting Person and Abingworth LLP, the Reporting Person is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of Abingworth LLP.</footnote>
        <footnote id="F3">ABV VII may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VII. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, Abingworth LLP, ABV VII or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Jeet Mahal, as Attorney-in-Fact</signatureName>
        <signatureDate>2022-03-23</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
